Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365750 · ClinicalTrials.gov registry record
COVID-19 Antibody and Reinfection Study
A clinical trial, sponsored by Kaiser Permanente.
- Completed
- Registry status
- 4,235
- Enrollment target
NCT05365750 is a clinical trial that has completed, run by Kaiser Permanente. The registered enrollment target is 4,235 participants.
The verdict
NCT05365750 has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- 4,235 participants
- Enrollment target
Study Summary
The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19. 3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,235 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05365750
The ClinicalTrials.gov registry entry for NCT05365750 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05365750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05365750 about?
NCT05365750 is a clinical study titled "COVID-19 Antibody and Reinfection Study". The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and s...
What is the current status of trial NCT05365750?
This trial is currently completed. The enrollment target is 4,235 participants. The study started on 2020-06-15. Estimated completion is 2024-12-31.
Who is sponsoring clinical trial NCT05365750?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.